Arctic Bioscience Signs 3-year Agreement Worth 75 Million NOK with Smerud Medical Research International to Conduct Clinical Study on Psoriasis
The agreement signed on Wednesday 3 March relates to the start of a phase IIb study for the treatment of mild to moderate psoriasis with the company's drug candidate, HRO350, developed from herring roe oil.The agreement signed on Wednesday 3 March relates to the start of a phase IIb study for the treatment of mild to moderate psoriasis with the company's drug candidate, HRO350, developed from herring roe oil. The purpose of the clinical study is to investigate the efficacy and safety of HRO350 and to establish the optimal dose. The study will include more than 500 patients and is planned